SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

CalciMedica, Inc. (CALC) (CIK 0001534133)
Date: March 6, 2026 · CIK: 0001534133 · Accession: 0000000000-26-002366

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293972

Date
March 6, 2026
Author
Division of
Form
UPLOAD
Company
CalciMedica, Inc. (CALC) (CIK 0001534133)

Letter

Re: CalciMedica, Inc. Registration Statement on Form S-3 Filed March 3, 2026 File No. 333-293972 Dear A. Rachel Leheny:

March 6, 2026

A. Rachel Leheny Chief Executive Officer CalciMedica, Inc. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Carlos Ramirez

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           March 6, 2026

A. Rachel Leheny
Chief Executive Officer
CalciMedica, Inc.
505 Coast Boulevard South, Suite 307
La Jolla, CA 92037

       Re: CalciMedica, Inc.
           Registration Statement on Form S-3
           Filed March 3, 2026
           File No. 333-293972
Dear A. Rachel Leheny:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Lauren Hamill at 303-844-1008 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Carlos Ramirez
</TEXT>
</DOCUMENT>